UK markets close in 4 hours 5 minutes

Astellas Pharma Inc. (YPH.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
8.75-0.01 (-0.14%)
At close: 09:49PM CEST
Currency in EUR

Valuation measures4

Market cap (intra-day) 16.21B
Enterprise value 19.70B
Trailing P/E 553.35
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)1.72
Price/book (mrq)1.75
Enterprise value/revenue 0.01
Enterprise value/EBITDA 0.12

Trading information

Stock price history

Beta (5Y monthly) 0.29
52-week change 3-35.78%
S&P500 52-week change 323.10%
52-week high 315.61
52-week low 38.53
50-day moving average 39.55
200-day moving average 311.29

Share statistics

Avg vol (3-month) 3170
Avg vol (10-day) 3254
Shares outstanding 51.79B
Implied shares outstanding 61.85B
Float 81.79B
% held by insiders 10.25%
% held by institutions 150.95%
Shares short 4N/A
Short ratio 4N/A
Short % of float 4N/A
Short % of shares outstanding 4N/A
Shares short (prior month ) 4N/A

Dividends & splits

Forward annual dividend rate 40.45
Forward annual dividend yield 45.09%
Trailing annual dividend rate 370.00
Trailing annual dividend yield 3798.54%
5-year average dividend yield 42.76
Payout ratio 42,452.83%
Dividend date 3N/A
Ex-dividend date 427 Sept 2024
Last split factor 25:1
Last split date 327 Mar 2014

Financial highlights

Currency in JPY.

Fiscal year

Fiscal year ends 31 Mar 2024
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 1.06%
Operating margin (ttm)-7.98%

Management effectiveness

Return on assets (ttm)1.80%
Return on equity (ttm)1.10%

Income statement

Revenue (ttm)1.6T
Revenue per share (ttm)894.27
Quarterly revenue growth (yoy)17.00%
Gross profit (ttm)N/A
EBITDA 244.7B
Net income avi to common (ttm)17.05B
Diluted EPS (ttm)0.02
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)335.69B
Total cash per share (mrq)187.23
Total debt (mrq)920.02B
Total debt/equity (mrq)57.65%
Current ratio (mrq)0.93
Book value per share (mrq)890.18

Cash flow statement

Operating cash flow (ttm)172.48B
Levered free cash flow (ttm)109.61B